Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.

Subjects

Subjects :

Adult
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl genetics
Humans
Male
Protein Kinase Inhibitors pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics
Point Mutation
Protein Kinase Inhibitors therapeutic use
Proto-Oncogene Proteins c-abl genetics

Details

Language :

English

ISSN :

2312-8852

Volume :

41

Issue :

1

Database :

MEDLINE

Journal :

Experimental oncology

Publication Type :

Academic Journal

Accession number :

30932408

Full Text :

https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12685